Market Cap 115.55M
Revenue (ttm) 590,000.00
Net Income (ttm) -45.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,771.19%
Debt to Equity Ratio 0.00
Volume 875,990
Avg Vol 655,974
Day's Range N/A - N/A
Shares Out 68.37M
Stochastic %K 96%
Beta 1.36
Analysts Strong Sell
Price Target $8.36

Company Profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative brea...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 952 7570
Address:
11055 Flintkote Avenue, San Diego, United States
BubbaLubsGreen
BubbaLubsGreen May. 15 at 8:46 PM
I believe $CRDF shorts have from this coming Monday through June 3 to cover most, if not all, of their positions. My level of conviction is high at this point. Could I be wrong? Of course I could be wrong. But I would never sit on this kind of high-risk if I were short right now. Friday morning, June 5, in the pre-market, I expect PR about how the phase 3 will be funded. By the end of that trading session, I expect the share price to be above $4. I consider that a pretty reserved estimate, not a far reaching one. Considering all the moving parts, the share price could potentially be much higher.
0 · Reply
Cutlass
Cutlass May. 15 at 8:21 PM
$CRDF We did receive refreshing news this week, that was vastly wanted/needed. 👍 🟢 I do think the Pfizer Acquisition Team is on a short leash after their mishaps with Trilllium, GPT and Seagen...the board probably has implemented all kinds of checks and balances, now an overloaded bureaucracy. What boards do, CYA. Good, let them slow step, and let some other company like Amgen sweep in and pull the trigger on CRDF to catch Pfizer flat footed. 🤠 Everyone have a pleasant May weekend. 🏡
0 · Reply
Blakeruss1
Blakeruss1 May. 15 at 8:08 PM
$CRDF exciting week of trading. Next few weeks will be life changing!! Congrats all longs
0 · Reply
Slide3
Slide3 May. 15 at 7:40 PM
$CRDF August $5 calls for 7 cents, I guess someone smarter than me knows an offering is on the way, I don't know. NFA
1 · Reply
anjajavyinvestor
anjajavyinvestor May. 15 at 5:50 PM
$CRDF on watch with upcoming ASCO data. imo shares will revalue to 5-10/share w/positive confirmatory p2 data. robust plk1 pipeline. $PFE standing nearby.
0 · Reply
biohuntress
biohuntress May. 15 at 5:31 PM
$CRDF if only Onva/ Folfiri vs SOC that could speed things up for AA
0 · Reply
mgmuc
mgmuc May. 15 at 5:20 PM
$CRDF ASCO doesn't hand out podium spots as gifts. An oral presentation slot is the ultimate scientific accolade.
1 · Reply
Messerschmittbf109
Messerschmittbf109 May. 15 at 5:18 PM
$CRDF …next minima
0 · Reply
Messerschmittbf109
Messerschmittbf109 May. 15 at 5:12 PM
$CRDF tomorrow 🤣will be monstrous
1 · Reply
BubbaLubsGreen
BubbaLubsGreen May. 15 at 4:10 PM
$CRDF https://www.clinicaltrialvanguard.com/news/cardiff-oncology-advances-onvansertib-to-phase-3-for-ras-mutated-colorectal-cancer/
1 · Reply
Latest News on CRDF
Cardiff Oncology reports Q1 EPS (18c), consensus (12c)

2026-05-14T21:00:37.000Z - 23 hours ago

Cardiff Oncology reports Q1 EPS (18c), consensus (12c)


Cardiff Oncology to present preclinical data on onvansertib

2026-04-17T20:14:54.000Z - 4 weeks ago

Cardiff Oncology to present preclinical data on onvansertib


Cardiff Oncology Transcript: KOL event

Mar 25, 2026, 4:30 PM EDT - 7 weeks ago

Cardiff Oncology Transcript: KOL event


Cardiff Oncology Transcript: Study result

Jan 27, 2026, 8:30 AM EST - 3 months ago

Cardiff Oncology Transcript: Study result


Cardiff Oncology initiated with an Outperform at Noble Capital

2026-01-05T14:01:22.000Z - 4 months ago

Cardiff Oncology initiated with an Outperform at Noble Capital


Cardiff Oncology Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 9:20 AM EST - 6 months ago

Cardiff Oncology Transcript: Stifel 2025 Healthcare Conference


Cardiff Oncology reports Q3 EPS (17c), consensus (21c)

2025-11-06T23:00:22.000Z - 6 months ago

Cardiff Oncology reports Q3 EPS (17c), consensus (21c)


Largest borrow rate increases among liquid names

2025-08-01T12:51:16.000Z - 10 months ago

Largest borrow rate increases among liquid names

ARKK ASST JMIA KULR LAC LQD LWLG


Cardiff Oncology announces data from CRDF-004 trial

2025-07-29T21:00:22.000Z - 10 months ago

Cardiff Oncology announces data from CRDF-004 trial


Cardiff Oncology Transcript: Study Update

Jul 29, 2025, 4:30 PM EDT - 10 months ago

Cardiff Oncology Transcript: Study Update


Cardiff Oncology reports Q2 EPS (21c), consensus (20c)

2025-07-29T20:26:34.000Z - 10 months ago

Cardiff Oncology reports Q2 EPS (21c), consensus (20c)


Largest borrow rate increases among liquid names

2025-07-16T12:45:24.000Z - 10 months ago

Largest borrow rate increases among liquid names

ABR BYND CAN ENVX INMB JMIA MBOT


Cardiff Oncology Names Roger Sidhu as Medical Chief

Jun 17, 2025, 4:39 PM EDT - 11 months ago

Cardiff Oncology Names Roger Sidhu as Medical Chief


Cardiff Oncology Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

Cardiff Oncology Earnings Call Transcript: Q4 2024


Cardiff Oncology to Present at Upcoming Investor Conferences

Feb 24, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology to Present at Upcoming Investor Conferences


Cardiff Oncology Transcript: Study Result

Dec 10, 2024, 8:00 AM EST - 1 year ago

Cardiff Oncology Transcript: Study Result


Cardiff Oncology Earnings Call Transcript: Q2 2024

Aug 8, 2024, 4:30 PM EDT - 1 year ago

Cardiff Oncology Earnings Call Transcript: Q2 2024


Cardiff Oncology Earnings Call Transcript: Q1 2024

May 2, 2024, 4:30 PM EDT - 2 years ago

Cardiff Oncology Earnings Call Transcript: Q1 2024


Cardiff Oncology Earnings Call Transcript: Q4 2023

Feb 29, 2024, 4:30 PM EST - 2 years ago

Cardiff Oncology Earnings Call Transcript: Q4 2023


Cardiff Oncology Earnings Call Transcript: Q3 2023

Nov 2, 2023, 4:30 PM EDT - 2 years ago

Cardiff Oncology Earnings Call Transcript: Q3 2023


Cardiff Oncology Transcript: Study Update

Sep 26, 2023, 5:00 PM EDT - 2 years ago

Cardiff Oncology Transcript: Study Update


BubbaLubsGreen
BubbaLubsGreen May. 15 at 8:46 PM
I believe $CRDF shorts have from this coming Monday through June 3 to cover most, if not all, of their positions. My level of conviction is high at this point. Could I be wrong? Of course I could be wrong. But I would never sit on this kind of high-risk if I were short right now. Friday morning, June 5, in the pre-market, I expect PR about how the phase 3 will be funded. By the end of that trading session, I expect the share price to be above $4. I consider that a pretty reserved estimate, not a far reaching one. Considering all the moving parts, the share price could potentially be much higher.
0 · Reply
Cutlass
Cutlass May. 15 at 8:21 PM
$CRDF We did receive refreshing news this week, that was vastly wanted/needed. 👍 🟢 I do think the Pfizer Acquisition Team is on a short leash after their mishaps with Trilllium, GPT and Seagen...the board probably has implemented all kinds of checks and balances, now an overloaded bureaucracy. What boards do, CYA. Good, let them slow step, and let some other company like Amgen sweep in and pull the trigger on CRDF to catch Pfizer flat footed. 🤠 Everyone have a pleasant May weekend. 🏡
0 · Reply
Blakeruss1
Blakeruss1 May. 15 at 8:08 PM
$CRDF exciting week of trading. Next few weeks will be life changing!! Congrats all longs
0 · Reply
Slide3
Slide3 May. 15 at 7:40 PM
$CRDF August $5 calls for 7 cents, I guess someone smarter than me knows an offering is on the way, I don't know. NFA
1 · Reply
anjajavyinvestor
anjajavyinvestor May. 15 at 5:50 PM
$CRDF on watch with upcoming ASCO data. imo shares will revalue to 5-10/share w/positive confirmatory p2 data. robust plk1 pipeline. $PFE standing nearby.
0 · Reply
biohuntress
biohuntress May. 15 at 5:31 PM
$CRDF if only Onva/ Folfiri vs SOC that could speed things up for AA
0 · Reply
mgmuc
mgmuc May. 15 at 5:20 PM
$CRDF ASCO doesn't hand out podium spots as gifts. An oral presentation slot is the ultimate scientific accolade.
1 · Reply
Messerschmittbf109
Messerschmittbf109 May. 15 at 5:18 PM
$CRDF …next minima
0 · Reply
Messerschmittbf109
Messerschmittbf109 May. 15 at 5:12 PM
$CRDF tomorrow 🤣will be monstrous
1 · Reply
BubbaLubsGreen
BubbaLubsGreen May. 15 at 4:10 PM
$CRDF https://www.clinicaltrialvanguard.com/news/cardiff-oncology-advances-onvansertib-to-phase-3-for-ras-mutated-colorectal-cancer/
1 · Reply
jakeguess
jakeguess May. 15 at 3:53 PM
$CRDF Quiet Period?? NO stand alone pr on fda meeting NO Conference call for busines update NO update on KOl meeting. NO UPDATE besides date on company presentation
0 · Reply
DBOCK
DBOCK May. 15 at 3:52 PM
$CRDF has never gone up on good news except in the early years when I jumped in.
1 · Reply
CoveredBridge
CoveredBridge May. 15 at 3:03 PM
$CRDF At the ASCO 2026 Annual Meeting, there will be a total of over 3,400 abstracts presented. Among these, there will be more than 450 oral presentations and numerous poster sessions showcasing valuable research and data in oncology. At the ASCO 2026 Annual Meeting, there will be a total of 30 rapid oral presentations scheduled. These presentations provide an opportunity for researchers to present their findings in a concise format, allowing for focused discussions on recent advancements in oncology. So with Cardiff’s Rapid Oral Presentation they are in rare company.
0 · Reply
CoveredBridge
CoveredBridge May. 15 at 2:48 PM
$CRDF Just wait till Dr. Heinz-Josef Lenz presents at ASCO next Thursday. I expect that will bring attention to Cardiff.
1 · Reply
McGinvests
McGinvests May. 15 at 2:00 PM
$CRDF same bullsh*t as always. CRDF should write papers on how to make good news look crap by burying it in mandatory announcements. Can’t wait for them to fumble ASCO…. Will probably announce raise the day before news.
1 · Reply
Blakeruss1
Blakeruss1 May. 15 at 1:57 PM
$CRDF trading like there will be a violent upside shortly
0 · Reply
J_A_M_E_S
J_A_M_E_S May. 15 at 1:45 PM
$CRDF To my fellow longs bummed with today's price action (so far). Take some deep breaths. This is a far less risky investment today than it was yesterday. Hold on to what you have. Buy more if you can. But sleep more soundly than you did a 2 nights ago. Will the FDA green light CRDF-005 ✅ Is AA on the table ⁉️ We don't know yet but good reason for optimism given 2023 meeting, strong patient benefit, high unmet need and limited toxicity. Is the PFS benefit strong ⁉️ We'll know soon enough at ASCO but certainly good enough for ASCO oral and the FDA Has the NMS issue been resolved⁉️ Not yet but we now know they're engaged in discussions. Roughly 95% of lawsuits settle and this isn't even a lawsuit yet. Expect NMS to get some royalties on future sales. How will we fund CRDF-005 and ops past 27Q1 ⁉️ We haven't the faintest idea yet but too much upside with high odds of success for some BP not too. AA is an important question remaining.
2 · Reply
suphawk85
suphawk85 May. 15 at 1:38 PM
$CRDF Here we go again ☹️
1 · Reply
BioGypsy
BioGypsy May. 15 at 1:20 PM
$CRDF 😂😂
0 · Reply
BullRun4
BullRun4 May. 15 at 12:57 PM
$CRDF something is off, I can’t seem to understand how this positive news from the FDA news not be seen as a positive catalyst. Stock price typically move with this sort of news and it is not going anywhere. That is very odd!! Any thoughts with this respect is greatly appreciated
6 · Reply
Huber65
Huber65 May. 15 at 11:46 AM
$CRDF with all the shorts they really had not been able to drive the price down even on bad market days . That is strange also .Until last few months it had been easy for them.
2 · Reply
PMD777
PMD777 May. 15 at 11:45 AM
$CRDF interesting day ahead with the broad pullback
0 · Reply